MDxHealth announced a $15 million acquisition of Bio-Techne's Exosome Diagnostics, including the CLIA-certified ExoDx Prostate test. The deal aims to enhance MDxHealth’s revenue growth and expand its cancer diagnostic platform by integrating proprietary exosome-based technology, broad intellectual property, and extensive clinical data across multiple cancers. The firm anticipates synergies within its existing tests and looks to foster strategic partnerships leveraging this platform. The transaction is expected to close in September 2025.